Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes ...Middle East

HANGZHOU, China and SAN FRANCISCO, Oct. 9, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical...

Hence then, the article about sciwind biosciences announces initiation of dosing in phase 1 clinical trial evaluating xw014 an oral small molecule glp 1 receptor agonist for the treatment of obesity and type 2 diabetes was published today ( Monday 10/10/2022 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes )

Also on site :

• Don't Do This Before Your Next Blood Test, Doctors Warn
• California colleges went big on online learning tools. Then the worst happened
• Costco Shoppers Are Racing to Grab This Ultimate Home Organization Item Before It Sells Out